Zomedica Announces "Friday at Four" Webinar on November 21st Providing Strategic Overview & Third Quarter 2025 Business Review

Rhea-AI Summary

Zomedica (OTCQB: ZOMDF) announced a special session of its "Fourth Friday at Four" investor webinar to be held on Friday, November 21, 2025 at 4:00 p.m. Eastern Time to provide strategic context for its product platforms, a review of third-quarter 2025 performance, and execution priorities for the remainder of 2025 and entry into 2026. The session will feature prepared remarks followed by a Q&A and a replay will be available after the event. Registration is open at the provided link for investors and stakeholders.

November session to provide strategic context for Zomedica's product platforms featured in the previous Fourth Friday at Four Webinars

ANN ARBOR, MI / ACCESS Newswire / November 11, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative diagnostic and therapeutic devices for equine and companion animals, today announced a special session of its "Fourth Friday at Four" investor webinar series. To accommodate the holiday calendar, this month's webinar will be held on the third Friday-November 21, 2025 at 4:00 p.m. Eastern Time.

The November program will provide a comprehensive overview of Zomedica's strategy-to-date, a review of third-quarter performance, and a look ahead at the Company's execution priorities to close out 2025 and enter 2026. Investors and interested stakeholders can register here: https://sholink.to/NovemberFriday.

Webinar Details

• Title: "Friday at Four" Strategic Overview & Third Quarter Review

• Date/Time: Friday, November 21, 2025, at 4:00 p.m. Eastern Time

• Registration: https://sholink.to/NovemberFriday

• Format: Prepared remarks followed by Question & Answer session

A replay will be available following the event for those unable to attend live.

About Zomedica

Zomedica is a leading equine and companion animal health company dedicated to improving animal health by providing veterinarians with innovative therapeutic and diagnostic solutions. Our gold standard PulseVet^® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi^® line of therapeutic devices, the TRUFORMA^® diagnostic platform, the TRUVIEW^® digital cytology system, the VetGuardian^® Zero Touch™ monitoring system, and Vetigel^® hemostatic gel, a revolutionary hemostatic agent that rapidly stops bleeding, each designed to empower veterinarians to deliver top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. Zomedica grew revenue 8% in 2024 to $27 million and maintains a strong balance sheet with approximately $54.4 million in liquidity as of September 30, 2025. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as we work to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information visit www.zomedica.com.

Follow Zomedica

• Email Alerts:http://investors.zomedica.com

• LinkedIn:https://www.linkedin.com/company/zomedica

• Facebook:https://m.facebook.com/zomedica

• X (formerly Twitter):https://twitter.com/zomedica

• Instagram:https://www.instagram.com/zomedica_inc

Cautionary Note Regarding Forward-Looking Statements

Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements and our ability to realize upon our business plans and cost control efforts.

Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to realize the anticipated growth opportunities from our acquisitions; uncertainty as to our ability to supply products in response to customer demand; supply chain risks associated with tariff changes; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products and purchase of consumables following adoption of our capital equipment; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

Investor Relations Contact:

Zomedica Investor Relations
Investors@zomedica.com
1-734-369-2555

SOURCE: Zomedica Corp.

View the original press release on ACCESS Newswire

FAQ

When is Zomedica's "Friday at Four" webinar covering the third quarter of 2025 (ZOMDF)?

The webinar is scheduled for Friday, November 21, 2025 at 4:00 p.m. Eastern Time.

What will Zomedica (ZOMDF) cover in the November 21, 2025 webinar?

The program will provide a strategy-to-date overview, a third-quarter 2025 review, and execution priorities for late 2025 and early 2026.

How can investors register for Zomedica's November 21, 2025 "Friday at Four" webinar (ZOMDF)?

Investors can register via the registration link provided in the announcement: https://sholink.to/NovemberFriday.

Will Zomedica (ZOMDF) provide a replay of the November 21, 2025 investor webinar?

Yes. A replay will be available after the event for those unable to attend live.

What format will Zomedica use for the November 21, 2025 webinar (ZOMDF)?

The session will use prepared remarks followed by a question-and-answer segment.